Taking Immunotherapy to the Next...

NASDAQ: INO

Taking Immunotherapy

to the Next Level

J. Joseph Kim, Ph.D.

President & CEO

October 2017

Forward Looking Statement

2

Our commentary and responses to your questions may contain

forward-looking statements, including comments concerning clinical

trials and product development programs, evaluation of potential

opportunities, the level of corporate expenditures, the assessment of

Inovio’s technology by potential corporate partners, capital market

conditions, timing of events, cash consumption, and other information

concerning factors that could cause actual results to differ materially

from those set forth in our Annual Report on Form 10-K for the year

ended December 31, 2016, our Form 10-Q for the period ended June

30, 2017, and other regulatory filings from time to time.

Leading the Development of DNA-based Immunotherapies

to Commercialization

3

Powerful platform,

multiple product

candidates

Efficacy demonstrated in

phase 2b study

Phase 3 enrolling;

Four additional

immunotherapy trials

with efficacy endpoints

Partnerships and

collaborations:

MedImmune,

Regeneron and Genentech

Our purposeDevelop

immunotherapies

and vaccines to

fight cancers and

infectious diseases

CELLECTRA

5PSP Device

• SynCon® antigen genetic code enables

precise targeting of cancer or pathogen

• Designed to break tolerance and

cover mutating strains

• Highly optimized SynCon plasmid + novel

CELLECTRA delivery generate optimal

antigen production IN THE BODY

• Activates robust functional CD8+ killer

T cell and antibody responses

• Phase 2b data published

• Favorable safety profile in over 1,500

subjects and 4,000 immunizations

• Significant antigen-specific immune

responses in almost 1,000 patients and

counting

Immune Responses by Design

4

SynCon

Immunotherapy

Optimized platform: SynCon® + CELLECTRA®

Immunotherapy Pipeline

5

Product Indication Preclinical Phase 1 Phase 2

VGX-3100

INO-1400

INO-5150

Phase 3

Prostate Cancer

hTERT (Multiple Solid Tumors)

Vulvar Neoplasia

Cervical Dysplasia

INTERNALLY FUNDEDPARTNER FUNDED

Preventive

INO-1800 Hepatitis B

MEDI0457 Head & Neck Cancer

Anticipated

Milestone

Initiated P3 2Q17

Initiated P2 2Q17

Reported data 3Q17Candidate for Out-licensing

Report data 4Q17

Report data 4Q17Candidate for Out-licensing Post-data

Initiated P1/2 checkpoint combo study 2Q17

INO-5401Glioblastoma Multiforme

Initiated P1/2 checkpoint combo study 4Q17

Initiate P1/2 checkpoint combo study 2H17

Bladder Cancer

VGX-3100: Fulfills Unmet Treatment Needs of HPV-Related

Precancers

6

EU: 15,000

US: 195,000

EU: 233,000

US: 13,400

EU: 2,514

Cervical

Vulvar

Anal

US: 23,000

Annual Incidence (HPV 16/18+ Precancers)

VGX-3100 is indicated for the treatment of the following precancerous

diseases caused by HPV types 16 and 18:

High grade Cervical Dysplasia

High grade Vulvar Dysplasia

High-grade Anal Dysplasia

• First-in-class HPV-specific immunotherapy

• Targets the major underlying cause of

anogenital cancer

• Treats pre-cancer without invasive surgery

1Massad LS, et al. Obstet Gynecol. 2013;121:829846.2Nobbenhuis MA, et al. Lancet. 2001;358:1782–1783.3Xi LF, et al. J Infect Dis. 2007;195:1340–1344. 4Nobbenhuis MA, et al. Br J Cancer. 2001;84:796–801.

Wright TC, et al. Obstet Gynecol. 1992;79:173–178.

IARC.Colposcopy and Treatmetn of Cervical Intraepithelial Neoplasia: A Beginner’s Manual. 2003.

Kyrgiou M, et al. Cochrane Database Syst Rev. 2015;CD008478

HPV Caused Pre-Cancers: Limitations of Surgery

40-50%

Recurrencepost-surgery

Anal

Vulvar

>50%


with clean

margins

Pain1

Cervical

10% - 16%

Recurrenceof CIN2/33,4 after

LEEP

HPV-16 DNA

detected in

patients after

LEEP4

23.5%

Loss of

Reproductive Health

Surgical Complications

Negative Psychosocial

Impact

40-50%


Anal

Vulvar

>50%


with clean

margins

Pain1

Cervical

10% - 16%


LEEP

HPV-16 DNA

detected in

patients after

LEEP4

23.5%

Loss of

Reproductive Health



Impact

40-50%


Anal

Vulvar

>50%


with clean

margins

Pain1

Cervical

10% - 16%


LEEP

HPV-16 DNA

detected in

patients after

LEEP4

23.5%

Loss of

Reproductive Health



Impact

HPV-Related Cervical HSIL Phase 3 Program

• VGX-3100: Targets HPV 16/18

subtypes; E6/E7 oncogenes

• Treats high-grade squamous

intraepithelial lesions (HSIL)

• Consists of two studies in parallel:

• REVEAL I (primary) n=198

• REVEAL II (confirmatory) n=198

• Randomized (2:1), double-blind,

placebo-controlled

• Dosing: month 0, 1, 3 (as in P2b)

• Primary endpoint: month 9

(as in P2b)

• REVEAL1: Study follow-up through

week 88 (as in P2b)

• REVEAL 2: Study follow-up through

week 40

• Report data from both studies in 2020

8

Primary Endpoint

• Regression of HSIL (CIN2/3)

AND clearance of HPV

16/18 in the cervix

Secondary Endpoints

• Safety/tolerability

• Regression of HSIL

• Virologic clearance of HPV-

16 and/or HPV-18

• Non-progression to cancer

• Clearance of HPV from non-

cervical anatomic locations

VGX-3100 has the potential to be the first treatment for HPV infection of the

cervix and the first non-surgical treatment for pre-cancerous cervical lesions.

Phase 2b Study Primary and Secondary Efficacy Endpoints Met

T Cell Responses Measured in Blood

• Efficacy correlates to immune responses

• PP and mITT p-values equal

• 167 subjects

• Paper published in The Lancet September 2015

• 1Strata-adjusted

Cervical HSIL regression

to low or normal

AND HPV clearance

VGX-3100 40.2%

Control 14.3%

Difference 25.9%

P-value1 p=0.001

T Cell Responses Measured in Tissue

*Statistically significant; bars are 95% Cl

VGX-3100800

600

400

200

0

0 5 10 15 20 25 30 35 40

Placebo

Study Week

VG

X-3

10

0 S

pe

cif

ic T

Ce

lls

1

Treatment at wks 0, 4, & 12

* * * *

Rationale for Combinations in Immuno-Oncology:

Turning “Cold” Tumors to “Hot” Tumors

Tumor infiltration of antigen-specific, functional

CD8+ T cells may prime patients for treatment with

checkpoint inhibitors and increase response rates

10

Checkpoint

combinations

• Improved response

rates

• Significantly

increased toxicity &

discontinuations

Checkpoint

monotherapies

• Durable anti-tumor benefit

• Low response rates; ~20% in most tumors

Checkpoints

combined with

Inovio cancer

vaccines

• Increase anti-tumor

benefit, without

adding toxicity

• Clinical studies

planned for 2017

- MEDI0457 with

MedImmune

- INO-5401 with

Regeneron and

Genentech

MEDI0457 (licensed out to MedImmune)

• Metastatic HPV-related squamous cell carcinoma of the head & neck (SCCHN)with persistent or recurrent disease after chemotherapy treatment.

• Combination with durvalumab (IMFINZI™) PD-L1 checkpoint inhibitor

• Phase 1/2 open label study: safety, immunological impact, objective response rate,progression-free survival and overall survival

• ~ 50 subjects. Enrolling.

INO-5401 (combination of 3 tumor-associated antigens: hTERT, PSMA, WT1)

• Advanced unresectable or metastatic urothelial carcinoma (bladder cancer)

• Combination with atezolizumab (TECENTRIQ®) PD-L1 checkpoint inhibitor

• Phase 1b/2 open-label trial: safety, immune response and clinical efficacy

• ~ 80 patients; ~ 60 will be PD-1/PDL-1 refractory patients. Enrolling.

INO-5401

• Newly diagnosed glioblastoma multiforme (GBM)

• Combination with REGN2810 PD-1 checkpoint inhibitor

• Phase 1b/2a open label trial: safety, tolerability, immunological impact, progression-free survivaland overall survival

• ~50 patients. Enrolling.

Immuno-Oncology Studies with Efficacy Endpoints

11

12

MEDI0457: Turning “Cold” Tumors to “Hot” Tumors in Phase 1

Before treatment

with MEDI0457

After treatment

with MEDI0457

Control: FoxP3 CD8

“Cold”

“Hot”

Vaccine Pipeline

13

Product Indication Preclinical Phase 1 Phase 2

PENNVAX®-GP

GLS-5700

GLS-5300

Phase 3

INO-4212

MERS

Zika

Ebola

HIV Reported data 2Q17

Discuss potential regulatory path 4Q17

Discuss potential regulatory path 4Q17

Publish data 4Q17

EXTERNALLY FUNDED

Infectious Disease Programs

Anticipated

Milestone

Positive Clinical Immune Response Data from Studies in

Healthy Volunteers: Emerging Infectious Diseases

14

MERS (GLS-5300) – Phase 1

• High levels of binding antibodies measured (ELISA) in 92% (57 of 62) of evaluated subjects

• Antigen-specific cytotoxic T-lymphocyte (CTL) responses observed

• 98% (61 of 62) generated an antibody and/or T cell response against MERS

HIV (PENNVAX-GP) – Phase 1

•Overall, 93% (71 of 76) evaluable vaccinated participants showed a CD4+ or CD8+ cellular immune response to at least one of the vaccine antigens (env A, env C, gag, or pol)

•Similarly, 94% (62 of 66) evaluated participants demonstrated an env specific antibody response

•None of the placebo recipients (0%;0 of 9) demonstrated either a cellular or an antibody response in the study

Ebola (INO-4201) – Phase 1


• T cell immune responses are being evaluated

Zika (GLS-5700) – Phase 1


• T cell immune responses are being evaluated

4Q17:

Publish Zika, Ebola, MERS

phase 1 immune response

and safety data

2H17:

Advance INO-5401

bladder cancer and GBM

programs with checkpoint

inhibitor to P1/P2

4Q17:

Report INO-1400

(hTERT) interim

immune response and

safety data

2Q17:

MEDI0457 checkpoint

inhibitor combo

P1/P2 trial initiated

3Q17:

Report INO-5150

(prostate) immune

response and safety

data (interim)

2017 Value Drivers and Milestones

15

2Q17:

VGX-3100 HSIL P3

& VIN P2 studies

initiated

2019:

Report on interim

P1/2 data from GBM

INO-5401 study

2019:

Report on interim

P1/2 data on

MEDI0457 study

2019:

Report on interim P1/2

data from Bladder

INO-5401 study

2018:

Report on Zika

vaccine Puerto Rico

study

2H18:

Report on interim

P1/2 MERS vaccine

Korea study data

2018-2019 Value Drivers and Milestones

16

1Q18:

Report INO-1800

HBV immune

response and safety

data (interim)

Management & Financials

Peter Kies

CFO

• Ernst & Young

• Experience with

growth companies

Mark L. Bagarazzi, MD

CMO

• Clinical research

experience incl. Merck

• Led clinical/regulatory

for shingles and

rotavirus vaccines;

DNA vaccine expert

Senior Management

18

J. Joseph Kim, PhD

President & CEO

• Decades of

biotechnology/

pharma management

• Merck: hepatitis A

and B vaccines

manufacturing;

HIV vaccine (Ad5)

R&D

Niranjan Y. Sardesai, PhD;

COO

• Extensive biotech

management and

product development

experience

• Led diagnostics

development for

mesothelioma, bladder

cancer, and ovarian

cancer for Fujirebio

Diagnostics

Board of Directors

19

George Bickerstaff

• Partner, M.M. Dillon & Co.

• Former CFO, Novartis

Pharma AG

Simon X. Benito

• Former Senior Vice

President, Merck

Vaccine Division

Avtar Dhillon, MD

Chairman, BOD

• Seasoned venture

capitalist and biotech

entrepreneur

Morton Collins, PhD

• General Partner,

Battelle Ventures and

Innovations Valley

Partners

Angel Cabrera, PhD

• President, George

Mason University

J. Joseph Kim, PhD

• President & CEO,

Inovio

Adel Mahmoud, PhD

• Professor, Princeton Univ.

• Former President, Merck

Vaccines

• Responsible for Gardasil®,

Zostavax®, Proquad® and

Rotateq®

David B. Weiner, PhD

• Executive VP, The

Wistar Institute;

Director, Vaccine

Center

Scientific Advisory Board

20

Anthony W. Ford-

Hutchinson, PhD

• Former SVP,

Vaccines R&D, Merck

• Oversaw development:

Singulair®, Januvia®,

Gardasil®,Zostavax®,

Proquad® and Rotateq®

Stanley A. Plotkin, MD

• Developed rubella and

rabies vaccines

• Oversaw Sanofi flu vaccine

• Emeritus Professor, Wistar

Institute

& University of

Pennsylvania

David B. Weiner, PhD

Chairman

• “Father of DNA

vaccines”

• Executive VP, The

Wistar Institute;

Director, Vaccine

Center

Financial Information

21

1October 31, 2017 2June 30, 2017

3 Due from ApolloBio Corp: up to $50M in signing fee, milestone and equity investment, the latter two contingent upon corporate and regulatory approvals in process

*July 25, 2017: raised $75M for 12,500,000 shares

Cash & short-term investments2 3 $92.0 M

0 MDebt2

Shares outstanding2 77.6 M

Recent share price1 $5.83

Market cap1 $525.3 M

*

*

Investment Thesis: Inovio Positioned with Multiple

Transformational Steps as an Immunotherapy Leader

Taking immunotherapy to the next level

22

Powerful technology

platform with multiple

cancer and infectious

disease product

candidates

Best-in-class data:

phase 2b CD8 killer

T cell/efficacy correlation

published in The Lancet

Phase 3 & phase 2 pre-

cancer studies including

three P1/P2 immuno-oncology

studies combining Inovio’s

technology with checkpoint

inhibitors

Validation: partners,

publishing, grants

INO:

NASDAQ

Appendix

Enhanced Cellular Delivery:

Key Enabler of DNA Immunotherapies

• DNA plasmids must get through

protective membrane into a cell

to work

• Best method to enhance cellular

uptake is electroporation

• SynCon® DNA plasmid and

CELLECTRA® delivery device

are phase 3 ready

24

CELLECTRA® 5PSP Device

CELLECTRA® 5PSP Electroporation Delivery Device

25

Array

Drug

0

1000

2000

3000

4000

5000

T Cell Responses By ELISpot Assay

1 x

10

-6 s

ple

en

ocy

tes

Immunized 3x with 15ug pNPresponses @2 wk post Imm

Display of GFP gene expression after

electroporation delivery into rabbit muscle

+EPE

P

Optim

ization

Design + Delivery = Improved Immune Responses

26

† HVTN 080 (N = 48 total). Responses shown against global peptides post-third dose, based on evaluable responders.

‡ HVTN 070 (N = 120 total). Responses shown against global peptides post-third dose, based on evaluable responders.

Clinical Confirmation of Inovio Electroporation BenefitHIV Antigen Response

• CD4 and CD8 intracellular

cytokine staining (IFN-γ, IL-2)

response associated with IL-12

and EP administration (2 clinical

studies) with HIV gag, pol, env

antigens/plasmids

• Dosing at 0, 4, 12 weeks

• Performed by independent HVTN

Core Lab at University of

Washington in NIH-sponsored

trials

0

10

20

30

40

50

60

70

80

90

- IL-12 + IL-12 - IL-12 + IL-12

CD4+ Responders (%) CD8+ Responders (%)

% R

es

po

nd

ers

27

+ EP

- EP

Spyros A. Kalams, et al., The Journal of Infectious Diseases 2013;208:818–29

Responses to three doses of vaccine

delivered with EP are greater than

responses to four doses of vaccine

delivered IM

P= 0.0003

P < 0.0001

Demonstrated Effect in Phase 2b Trial of VGX-3100

28

Placebo-Controlled,

Randomized, Double Blind

• VGX-3100 SynCon® product

for HPV-related pre-cancers

• Targets HPV 16/18 subtypes,

E6/E7 oncogenes

• Females, age 18-55 (n=167)

• High-grade cervical

dysplasia (CIN2/3); HSIL

• HPV 16 and/or 18 positive

• 3:1 randomization

• Dosing: month 0, 1, 3

Primary Endpoint

• Regression of CIN2/3

(HSIL) to CIN1 or

normal (week 36)

Secondary Endpoint

• Regression of CIN2/3

to CIN1 or normal and

clearance of HPV

(week 36)

Phase 2b Achieves Primary and Secondary Endpoints

29

• Efficacy correlates to immune responses

• PP and mITT p-values equal

• 167 subjects

• Paper published in The Lancet September 2015

• 1Strata-adjusted

Regression high grade

to low grade cervical

dysplasia or normal

Dysplasia regression

to low or normal AND

HPV clearance

Lesion

regression

to normal

VGX-3100 49.5% 40.2% 40.2%

Control 30.6% 14.3% 16.7%

Difference 18.9% 25.9% 23.5%

P-value1 p=0.017 p=0.001 p=0.006

Groups

Primary

Endpoint

Secondary

Endpoint

Primary –

Post Hoc

Phase 3

Primary Endpoint

• On February 13, 2017, Inovio entered into a Collaboration and License Agreement

with ApolloBio Corporation

• ApolloBio to receive exclusive rights to VGX-3100 within Greater China (China, Hong King, Macao, Taiwan)

• Potential inclusion of The Republic of Korea within three years of the Effective Date

• Inovio to receive upfront cash payment of $15M(1)

• Inovio to further receive up to $20M based upon achievement of VGX-3100 regulatory milestones (US,

China, Korea), and double digit royalties on all net sales of VGX-3100 within the licensed territory

• Under a separate Stock Purchase Agreement, ApolloBio to purchase $35M(2) of

Inovio common stock

• ApolloBio will pay $8.20 per share, which is based upon the 30 trading day volume weighted average price

encompassing a period prior to and following FDA’s lifting of the VGX-3100 clinical hold

• It is anticipated to close during the second half of 2017

• Both agreements are subject to closing conditions including the final approval of

ApolloBio’s Board of Directors and shareholders, as well as regulatory and currency

approvals required by The People’s Republic of China

30

(1) $12M of the $15M was tied to the FDA’s lifting of the VGX-3100 Phase 3 pre-initiation clinical hold. The clinical hold was

lifted on June 6th 2017.

(2) The amount may potentially be less than $35M, such that ApolloBio would not become the largest shareholder of Inovio.

Inovio and ApolloBio Transaction: VGX-3100

First Partnership to Initiate Immuno-Oncology Strategy

31

Products

MEDI0457 (previously INO-3112)

HPV-driven cancer immunotherapy

+ 2 new R&D products

Upfront

Payment$27.5 million

Development

CostsAll development costs

Milestone

Payments$700 million

RoyaltiesUp to double digit tiered royalties on MEDI0457 +

royalties for additional cancer vaccine products

AstraZeneca/MedImmune(deal signed August 2015)

MedImmune intends to study MEDI0457 in combination with

selected immuno-oncology molecules within its pipeline

Perforin

Gra

nu

lys

in

Gra

nzym

e A

Gra

nzym

e B

• Lytic phenotype: patient PBMCs stimulated 120 hours in vitro with antigen. No co-

stimulation; no cytokine added at any time.

• Activation markers: CD38, CD69, CD137

• Lytic proteins: perforin, granzyme A, granzyme B, granulysin

MEDI0457 Drives Antigen Specific CD8+ T Cells with Lytic

Phenotype in Patient with HPV16/18 Head & Neck Cancer

32

HPV 16/18

Specific CD8+

T Cell

Activation

HPV 16/18

Specific CD8+

T Cell

Activation and

Expression of

Lytic Proteins

8 of 9 patients show

CD8+ responses

to MEDI0457

Induction of CD8+ Activation, Lytic Protein Synthesis, and Humoral Immune

Responses to HPV 16 and 18 in MEDI0457 Treated HNSCC Patient

33

0 .0

0 .2

0 .4

0 .6

0 .8

1 .0

IN O -3 1 1 2

% C

D8

/CD

38

& C

D6

9 &

CD

13

7

B e fo r e

IN O -3 1 1 2

A fte r

IN O -3 1 1 2

Representative

patientBefore

MEDI0457

After

MEDI0457Before

MEDI0457After

MEDI0457

Before

MEDI0457

After

MEDI0457

MEDI0457

Emerging Infectious Disease Vaccine Opportunities

• Inovio DNA vaccine platform demonstrates rapid design, manufacturing,

and clinical development of products for emerging diseases

• Commercialization drivers

• Grants, such as DARPA $45M Ebola award, Gates $8.8M, IVI grant for MERS

• Priority review voucher potential

• Stockpiling contracts: scale manufacturing

• Coalition for Epidemic Preparedness Innovations (CEPI)

• “The coalition will also develop so-called platform technologies—experimental

approaches to producing new vaccines that use synthetic DNA to kick-start an

immune response.”

– MIT Technology Review

• Newly formed CEPI is largest-ever initiative to finance/develop new vaccines to address

emerging infectious diseases

• Initial $540M investment: Germany, Japan, Norway, Bill & Melinda Gates Foundation and

Wellcome Trust

34

Rapid response technology platform desired by health authorities

to fight emerging infectious diseases

dMAb™ Products: Multiple Immune Mechanisms & Products

Inovio’s DNA-based monoclonal antibody products target:

35

Cancers Infectious Diseases

• Influenza A

• Influenza B

• Pseudomonas

• MRSA/Staph

• Ebola

• MERS

• Dengue

• CHIKV

• Other infectious

diseases

• Checkpoint Inhibitors

(CI)

• PD-1

• PD-L1

• 4 additional CIs

• Herceptin

• Anti-Tregs

• Other anti-cancer

pathways

DARPA funded programs

Promising Preclinical dMAb Data

DARPA awards $57M to advance dMAb application and develop products for Ebola,

influenza and antibiotic resistant bacteria

36

0%

20%

40%

60%

80%

100%

Tu

mo

r C

lea

ran

ce

(%

)

Cancer dMAbProstate cancer model in mice

(Unpublished data)

dMAb (7 of 10) Control (0 of 10)

70%

0%0%

20%

40%

60%

80%

100%

Pro

tec

tio

n in

Ch

all

en

ge w

ith

Den

gu

e

Vir

us

(%

)

Dengue dMAb(Nature Scientific Reports 2015)

dMAb (10 of 10) Control (0 of 10)

100%

0%

Successful start of phase 3 studies

37

Expansion Into Brand New Facilities at Both SD and PHL to

Support Next Phase of Growth

38

• Completed/Planned next wave of

expansion – New device manufacturing

facility in San Diego (~52,000 sq. ft). Build

out and move in 07/17/2017; ~30,000 sq.

ft additional space leased in Plymouth

Mtg HQ.

• Consolidated operations by functional

areas in San Diego (2 sites) and

Plymouth Mtg

The People Who Make it HappenBoard of Directors

J. Joseph KimPresident & CEO Rami Kim-Ko

Administrative Manager

Thomas KimSr VP Gen Counsel &

Corp Secretary

Thomas ManciniSr. IP Counsel

Maggie Hewlett PT, File Clerk

Paul IrvineIP Paralegal

Rebecca PiranianParalegal

Ann HastingsAsst, Contract Mgmt

Peter KiesCFO

Maggie CampbellDir Acct & FInance

Catherine HaController

Jeff RichardsonVP, Strategic

Relations

Glenda DidienneManager, General

Operations

Angelica ChavezOffice Coordinator

Victoria AkpanOffice Coordinator

Thomas HongComm Associate

Ann Hartman Sr Financial Analyst

Erin ButlerAsst Controller

Lisa DanielsAssoc Dir, Human

Resources

Ronnie WenSr. Mrg, Acct, VGXP

Lynn NgoMgr, Financial

Reporting

Joan CoyleSr Acct Contractor

Marvin BautistaFacilities Supervisor

Charles HaganTalent Acquisition

Partner

Linda McLaughlin Manager, HR

Lucy OmarHR Assistant

Shanjida SharnaReceptionist

Denise WescottOffice Manager

Emily MilesAP Clerk

(Contractor)

Iris RicoMgr, Accounting

Ruthie DeGuzmanSr Accountant

Urthelyn Addae-Mensah

Sr Accountant

Lan CaoStaff Accountant

Carolina GarciaAP Clerk

Guadalupe CajicaAccounting Assoc

Niranjan Y. SardesaiCOO

Stephen KemmerrerVP, Engineering Development

EJ BrandrethVP, Quality

Daniel JordanVP, Device Mfg

Operations

Paul SteadVP, BD

Jennifer LauxVP, Commercial

Keiko SimonVP, Alliance and Program Mgmt

Bill RuggerioDirector of IT

Beat StadelmannDirector, Electrical

Engineering

Michael MaiSr Electrical Eng

Charu MatherPrincipal Elec Eng



Anu SoundarajanSW Validation Engineer

(Contractor)

Brad FisherV&V Engineer

(Contractor)

Daniel UngerSW Validation Engineer

(Contractor)

Brad FisherV&V Engineer

(Contractor)

Brian WatermanAssoc Dir, Mfg/Eng

Felipe BuenrostroDistribution Assoc

Tommy PhothirathAssembler II (Contractor)

Nathan ManczarekDirector, Device

Quality; Mgmt Rep

Yumi NakamuraQA System Admin

William RayMgr, Quality Eng/QC

Brian BurtonDevice Service Tech

(Contractor)

John BatesQC Technician

(Contractor)

Nhi TsanQA Sample

Inventory Specialist

Matthew GephartQuality Engineer

Robert WixeySr Sup, Compliance/

Lead Auditor

Bentley TamQuality Systems

Specialist

Ronald SmithSr Supervisor,

Bioanalytics QA

Michelle BeveridgeMgr, Clinical QA

Christian FloccoSr Mgr IT CSV

Greg PearlSr. Mgr, BSA

Denise HurleyIT Business Analyst

(Contractor)

Dan MarkleApplicant Specialist

(Contractor)

Mark LabelleSr. Mgr, Infrastructure

Architecture

Mark SturrockSr Systems Engineer

Gonzalo PachecoIT Systems Admin

Kevin HelmboldIT Site Support III

Jennifer LataAssociate Director

PM

Sandra LeeProgram Manager

Chelsey NehilaSr.Assoc

.Commercial

James BarlowSr. Dir,Commercial

Mark TwymanSr. Dir, Commercial

Kevin KirbySr Mfg Project Eng

Kevin WyrwichMfg Electrical Eng

David DinubiloMfg Project Eng

Alison RileyMfg Eng I

Gordon JungSr Mfg Eng

Linda CampbellSr. Technical Writer

Luis RamosProduction Supervisor

Anjovel CastroAssembler Lead

Ismael Cardenas-Lopez

Elec Test Tech Lead

Tap TruongSr Electrical Tech

Eric Cochran Electrical Test Tech.

Joel LorenzoAssembler II

Jestoni Canlas Assembler II

Jeffrey SanchezAssembler II

Gabriel TobiasEng Elec Tech

Kevin KemmererMechanical Eng II

Victor CovarrubiasElectrical Eng

Dinh WinterEng Tech

Jasmin GamillaSenior Systems

Engineer

Jeby MacaraegEng Tech

Karen RoycroftDir, Clinical QA

Joseph HessQA Associate

Janet NelsonAssoc Dir, Device

Quality

John VaughtRA/QA Associate

Ravinder SinghSr Mfg & Service

Technician

Thanh LeQC Technician

Jose GastonQC Technician

Tina GutierrezQC Technician

Sopida InjunQC Technician

Luigi TamburroQuality Engineer

Jose Luis HernandezMgr, Quality Sys/

Doc Control

Saul RodriguezDoc Control

Specialist

Sree ChandrasenanSoftware Manager

Mark BagarazziCMO

Sharon MorganSr. Exec Admin

Scott WhiteVP CD Infectious

Diseases

Ami Shah BrownVP, Reg Affairs

Robert JubaVP, Bio Mfg/Clinical

Supplies Mgmt

Jessica LeeVP, Clinical Ops & Global Integration

Lester GibbsDir, Regulatory

Affairs

Tracy JanusDir, Reg Affairs, CMC

Maurice BriggsDirector, Reg Affairs

Heather L. SinselMngr, Reg Ops and

Submissions

Renuka KrishnanDir, Reg Affairs, Medical Devices

Cheng ZhangAssoc Dir, Reg Affairs,

Medical Devices

David GramseManager, Reg Affairs,

Medical Devices

Chalise JacksonClin Supplies Mngr

Mike DallasSr. Dir Biostatistics

Trevor McMullanSr Biostatistician

Xiaoyun ZhangSr Biostatistician

Timothy HerringEpidemiologist

Susan DuffDirector, Data Mgmt

Sandra OyolaMngr Data Mgmt

Meredith LandauMngr Data Mgmt

Ildiko Csiki VP, Clin Dev,

Oncology

Jeff Skolnik VP, Clin Dev,

Oncology

Prakash Bhuyan VP, Clinical Dev

Marie Leimkuhler Dir, Clinical Ops

Kimberly HunsickerSr. Dir, Clinical Ops

Patricia Green-Amsler

Sr Dir, Clin Compli

Matthew ParrisDir Clinical Ops

Diane StinsonSr Outsourcing Mgr

Rachel ElwardLead, Med Device

Hedieh BadieClinical Device

Trainer

Elliott BlackwoodClinical Device

Trainer

Teresa LeanoDevice Trainer

Noel RolonSr. Dir, Clinical Ops

Nick JeffersOutsourcing Mgr

Linda PetersonAssoc Dir, Oncology

Sybil VargheseClinical Scientist

Divya ShahSr CS

Kathleen Marcozzi-Pierce

Sr. CPM

Percilla ChangCTA

Clay ChurchillCPM

Bridgette WhiteSr. CPM

Ashley SantoAssociate Scientist

Helaine ZwangerCS

Robert E. SamuelsAssoc Clin Prog Dir

Grace WarkulwizAssoc Scientist

Pamela Bachman Sr Clin Comp Assoc

Carol HelperSr Mgr, Clin Comp

Ashley PopelikSr Mgr, Clin Comp

Deborah CarmanAssociate, Clin Comp

Thomas PitmanTechnical Writer

Mary GiffearAssoc Dir, Clin Stu

Malissa DiehlSr CS

Michele BialeckiCTA

Amy ScheelerSr. CS

Gabrielle FarrellCoOp

Jeff SmithCTA

Lizbeth RomeroClinical Trial Assoc

Maureen O’ConnellCS

Brian SacchettaAssoc. CS

Kamal BhattAssoc Clinical Prog

Director

Nicholas CarrollAssoc CS

Samantha Rosencranz

CTA

Drishty MangroliaSr CS

Bryan StoneCTA

Robin ElderMgr, Pharmacovigilance

Patricia CampbellDrug Safety Associate

Tamara HowardSr CS

Amanda BuschAssociate Scientist

Laurent HumeauVP R&D

Amir KhanSr Dir Product Devel

Jean BoyerSr Dir, Analytical

Sciences

Emma MastellerSr. Dir, Immuno-

Oncology

Kate BroderickSr. Director, R&D

Matthew Morrow Director

Immunology &

Kim KraynyakLead, Immunology

David Frantz, PM, Preclinical

Dawson KnoblockProd Dev Scientist

Li LiuProduct Dev

Scientist

Albert SylvesterProduct Dev Assoc

Naseem ProstakProduct Dev Assoc

Nikki MarshallProduct Dev

Scientist

Charles ReedProtein Engineer

Jian YanAssoc Dir Antigen

Design & Discovery

Anna SlagerProduct Dev

Scientist

Neil CoochProduct Dev

Scientist

Jing ChenProduct Dev

Scientist

Bradley GarmanProduct Dev Assoc

Angela BrakhopScientific Writer

(Part-time)

Jeffrey AllenAssoc Dir,

Pharmacology/Toxicology

Megan WisePostdoctoral Fellow

Bernadette FerraroSr Scientist

Jewell WaltersScientist

Aleksandr DolgoterAssoc Scientist

Phoebe ValdesRA II

Justin ArndtRA I

Alexander QuachRA I

Loubna MamezaRA I

Anna PyzelRA I

Aubree AntonRA I

Kelsie DickersonRA I

Lannie NguyenRA I

Lindsay SakataAssociate Scientist

Karlie BergRA II

Sophie TanRA II

Jocelyn CheungAssociate Scientist

Mina NajiClin Immunological

Coordinator

David ValentaSr Mgr, Analytical

Immunology

Kristine GermarScientist

Shane DesforRA I

Christian RohRA I

Dennis van de GoorRA II

Dinah AmanteAssoc Scientist

Joseph AgnesSr. Scientist

Patrick PezzoliDir, Product

Characterization

Nathan KeysRA I

Joseph FaderRA I

Roi FerrerRA I

Alysha VuRA I

Alicia MenendezAssoc. Scientist

Maria YangProduction Scientist

Francisco Vega VegaRA I

Brian LeeRA I

Melissa GutierrezRA II

Lauren GitesRA II

Janess MendozaOperations Group

Lead

Jacklyn NguyenRA I

Jacklyn NguyenRA I

Nina SchommerScientist

Bryan YungRA II

Holly PughRA II

Katherine SchultheisScientist

Trevor SmithAssociate Dir, R&D

Dustin ElwoodScientist

Sergey LyubinetskyCloning Scientist

Xinggang LiuRA II

Ghiabe GuibingaScientist

Preeti BangaloreRA II

Stephanie RamosAssociate Dir, R&D

Eric SchadeBioengineer RA I

Alison GenerottiBioengineer RA I

Paul FisherBioengineering

Scientist

Jay McCoyAssoc Dir, Device

R&D

JingJing JiangScientist

• Aug 2014: Total 86 [PM (36); SD (45); Contractors (2); Interns (3)]

• Aug 2015: Total 135 [PM (57); SD (64); Contractors (5); Interns (9)]

• Aug 2016: Total 214 [PM (83); SD (102); Contractors/Interns (29)]

• Jul 2017: Total 271 [PM (116); MR (83); WR (59); Contractors (13)]

Inovio Clinical Pipeline

40

Product Name Indication Preclinical Phase 1 Phase 2

VGX-3100

INO-1400

INO-5150

Phase 3

VGX-3100

Prostate Cancer Therapeutic

hTERT (Multiple Solid Tumors) Therapeutic

Vulvar Neoplasia Therapeutic

Cervical Dysplasia Therapeutic

INO-5401 Bladder Cancer Therapeutic

EbolaINO-4212

PENNVAX®-GP HIVPreventive/

Therapeutic

INO-1800 Hepatitis B Therapeutic

Preventive

EXTERNALLY FUNDED

Infectious Disease

Programs

INTERNALLY

FUNDED

Cancer Programs

EXTERNALLY

FUNDED

Cancer Programs

GLS-5300 MERS Preventive

INO-5401 Glioblastoma Multiforme Therapeutic

Zika PreventiveGLS-5700

HPV-Related

Precancers

Immuno-

Oncology

Infectious

Diseases

MEDI0457 Head & Neck Cancer Therapeutic

Taking Immunotherapy to the Next...

Documents

Transcript of Taking Immunotherapy to the Next...